<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Elisence – Phase 9: Diabetes &amp; Metabolic Health</title>

    <!-- Elisa chat widget script -->
    <script defer src="elisa-chat.js"></script>

    <style>
        :root {
            --bg-space: radial-gradient(circle at top, #04101f 0%, #020617 45%, #000000 100%);
            --text-main: #e8f4fc;
            --text-soft: #cbd5f5;
            --text-muted: #94a3b8;
            --accent: #38bdf8;
            --accent-soft: #7dd3fc;
            --card-bg: rgba(15, 23, 42, 0.96);
            --card-border: rgba(56, 189, 248, 0.9); /* subtle diabetes/GLP-1 tint */
            --shadow-strong: 0 0 28px rgba(56, 189, 248, 0.7), 0 0 52px rgba(15, 23, 42, 0.9);
        }

        * {
            box-sizing: border-box;
        }

        body {
            margin: 0;
            min-height: 100vh;
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, Helvetica, sans-serif;
            background: var(--bg-space);
            color: var(--text-main);
        }

        /* Top dot + label */
        .top-dot {
            position: fixed;
            left: 16px;
            top: 16px;
            width: 11px;
            height: 11px;
            border-radius: 999px;
            background: #38bdf8;
            box-shadow: 0 0 16px rgba(56, 189, 248, 0.95);
            z-index: 900;
        }

        .top-dot-label {
            position: fixed;
            left: 36px;
            top: 11px;
            padding: 6px 10px;
            border-radius: 999px;
            border: 1px solid rgba(148, 163, 184, 0.6);
            background: rgba(15, 23, 42, 0.9);
            font-size: 0.7rem;
            letter-spacing: 0.18em;
            text-transform: uppercase;
            color: #e5f2ff;
            z-index: 900;
        }

        /* Side navigation (pills) */
        .side-nav {
            position: fixed;
            right: 32px;
            top: 50%;
            transform: translateY(-50%);
            display: flex;
            flex-direction: column;
            gap: 12px;
            z-index: 950;
        }

        .nav-btn {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            padding: 0.65rem 1.5rem;
            border-radius: 999px;
            border: 1px solid rgba(148, 163, 184, 0.75);
            background: radial-gradient(circle at top left,
                rgba(56, 189, 248, 0.32),
                rgba(15, 23, 42, 0.96));
            color: #e2e8f0;
            font-size: 0.78rem;
            letter-spacing: 0.16em;
            text-transform: uppercase;
            text-decoration: none;
            box-shadow: 0 0 14px rgba(15, 23, 42, 0.9);
            backdrop-filter: blur(12px);
            transition: transform 0.16s ease,
                        box-shadow 0.16s ease,
                        border-color 0.16s ease,
                        background 0.16s ease;
        }

        .nav-btn:hover {
            transform: translateX(-2px);
            border-color: rgba(56, 189, 248, 0.95);
            box-shadow: 0 0 22px rgba(56, 189, 248, 0.9);
            background: radial-gradient(circle at top left,
                rgba(56, 189, 248, 0.45),
                rgba(15, 23, 42, 0.98));
        }

        .nav-btn:active {
            transform: translateX(-1px) translateY(1px) scale(0.99);
        }

        /* Layout wrapper */
        .page-wrapper {
            max-width: 1200px;
            margin: 0 auto;
            padding: 96px 1.8rem 72px 1.8rem;
        }

        .hero-area {
            margin-bottom: 2.4rem;
        }

        .phase-hero-card {
            background: radial-gradient(circle at top left,
                rgba(56, 189, 248, 0.35),
                rgba(15, 23, 42, 0.98));
            border-radius: 26px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.6rem 1.8rem;
        }

        .phase-hero-inner {
            display: flex;
            gap: 1.8rem;
            align-items: stretch;
        }

        .phase-hero-logo-box {
            flex: 0 0 290px;
            border-radius: 22px;
            background: radial-gradient(circle at top, #0b1220, #020617);
            display: flex;
            align-items: center;
            justify-content: center;
            padding: 0.75rem;
            box-shadow: 0 0 24px rgba(15, 23, 42, 0.9),
                        0 0 40px rgba(15, 23, 42, 0.9);
        }

        .phase-hero-logo {
            width: 100%;
            max-width: 360px;
            height: auto;
            border-radius: 18px;
            box-shadow: 0 0 28px rgba(15, 23, 42, 0.95);
        }

        .phase-hero-text-box {
            flex: 1;
            display: flex;
            flex-direction: column;
            justify-content: center;
        }

        .phase-label {
            font-size: 0.78rem;
            text-transform: uppercase;
            letter-spacing: 0.18em;
            color: var(--text-muted);
            margin-bottom: 0.3rem;
        }

        .phase-title {
            font-size: 1.9rem;
            letter-spacing: 0.06em;
            text-transform: uppercase;
            color: #f9fafb;
            margin: 0 0 0.35rem 0;
        }

        .phase-subtitle {
            font-size: 0.95rem;
            letter-spacing: 0.14em;
            text-transform: uppercase;
            color: #7dd3fc;
            margin-bottom: 0.6rem;
        }

        .phase-lead {
            font-size: 0.98rem;
            color: var(--text-soft);
            margin-bottom: 0.7rem;
        }

        .phase-hero-bullets {
            margin: 0.3rem 0 0 0;
            padding-left: 1.1rem;
            font-size: 0.9rem;
            color: #e0f2fe;
        }

        .phase-hero-bullets li {
            margin-bottom: 0.2rem;
        }

        /* Phase detail cards */
        .phase-main {
            max-width: 1100px;
            margin: 0 auto;
        }

        .info-card {
            background: var(--card-bg);
            border-radius: 20px;
            border: 1px solid var(--card-border);
            box-shadow: var(--shadow-strong);
            padding: 1.8rem 1.7rem;
            margin-bottom: 1.8rem;
        }

        .info-card h2 {
            margin-top: 0;
            margin-bottom: 0.85rem;
            font-size: 1.3rem;
            color: var(--accent-soft);
        }

        .info-card h3 {
            margin-top: 1.1rem;
            margin-bottom: 0.4rem;
            font-size: 1.02rem;
            color: #7dd3fc;
        }

        .info-card p {
            margin: 0.35rem 0;
            font-size: 0.94rem;
            color: #e5f2ff;
        }

        .info-card ul {
            margin: 0.45rem 0 0.25rem 1.2rem;
            padding-left: 0.3rem;
        }

        .info-card li {
            margin-bottom: 0.32rem;
            font-size: 0.93rem;
        }

        .subtle {
            font-size: 0.88rem;
            color: var(--text-muted);
        }

        /* Responsive */
        @media (max-width: 900px) {
            .page-wrapper {
                padding: 80px 1.2rem 80px 1.2rem;
            }

            .phase-hero-inner {
                flex-direction: column;
            }

            .phase-hero-logo-box {
                flex: 0 0 auto;
            }

            .side-nav {
                right: 50%;
                bottom: 18px;
                top: auto;
                transform: translateX(50%);
                flex-direction: row;
                flex-wrap: wrap;
                justify-content: center;
                gap: 10px;
            }

            .nav-btn {
                font-size: 0.7rem;
                padding: 0.6rem 1.1rem;
            }

            .info-card {
                padding: 1.5rem 1.35rem;
            }
        }
    </style>
</head>
<body>

<div class="top-dot"></div>
<div class="top-dot-label">ELISENCE</div>

<nav class="side-nav">
    <a class="nav-btn" href="index.html">Home</a>
    <a class="nav-btn" href="index.html#phases">Phases</a>
    <a class="nav-btn" href="about.html">About</a>
    <a class="nav-btn" href="story.html">Story</a>
    <a class="nav-btn" href="video.html">Videos</a>
    <a class="nav-btn" href="contact.html">Contact</a>
</nav>

<div class="page-wrapper">
    <!-- HERO -->
    <section class="hero-area">
        <div class="phase-hero-card">
            <div class="phase-hero-inner">
                <div class="phase-hero-logo-box">
                    <img src="elisence.png"
                         alt="Elisence – Global Digital Health & Humanity Platform"
                         class="phase-hero-logo">
                </div>
                <div class="phase-hero-text-box">
                    <div class="phase-label">PHASE 9</div>
                    <h1 class="phase-title">Diabetes &amp; Metabolic Health Intelligence</h1>
                    <div class="phase-subtitle">
                        GLUCOSE · WEIGHT · MEDICATION · LIFESTYLE · SAFE &amp; NON-DIAGNOSTIC
                    </div>
                    <p class="phase-lead">
                        Phase 9 is the Diabetes &amp; Metabolic Health brain of Elisence. It takes glucose readings,
                        weight trends, GLP-1 and other medications, food patterns, sleep and movement, and turns
                        them into <strong>non-diagnostic, audit-ready metabolic insights</strong> that support
                        citizens, clinicians and ministries – without ever replacing a doctor or a diabetes team.
                    </p>
                    <ul class="phase-hero-bullets">
                        <li>Designed around real life with diabetes, not just lab numbers.</li>
                        <li>Non-diagnostic, guideline-aware patterns instead of hard medical decisions.</li>
                        <li>Five-language foundation: EN, FA, AR, TR, RO from day one.</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- DETAIL CARDS -->
    <main class="phase-main">

        <!-- 1. WHAT PHASE 9 IS -->
        <section class="info-card">
            <h2>1. What Phase 9 Really Is</h2>
            <p>
                Phase 9 is Elisence’s structured <strong>Diabetes &amp; Metabolic Health Intelligence layer</strong>.
                It does not diagnose or prescribe. Instead, it organises scattered signals – glucose, weight,
                medication, meals, activity, sleep, stress – into patterns that are easy to understand, share and review.
            </p>
            <p>
                The goal is clear: give people living with diabetes and metabolic risk a safe companion that helps them
                <strong>see trends, understand their own body</strong> and have better conversations with clinicians,
                while strict rules keep every output inside a non-diagnostic, wellness-aligned boundary.
            </p>
            <p>
                Phase 9 is built to support:
            </p>
            <ul>
                <li>People with type 2 diabetes or pre-diabetes using lifestyle and medication to stay in range.</li>
                <li>GLP-1 and other weight-loss medication users who need structured tracking and safety nudges.</li>
                <li>Citizens at metabolic risk (weight, blood pressure, family history) who want prevention and coaching.</li>
                <li>Clinicians and clinics that need clean, structured data instead of chaotic screenshots and logs.</li>
                <li>Ministries and insurers that want anonymised, k-anonymous insight into real-world metabolic health.</li>
            </ul>
        </section>

        <!-- 2. CORE ENGINE & DATA MODEL -->
        <section class="info-card">
            <h2>2. Core Engine &amp; Data Model</h2>
            <p>
                Under the surface, Phase 9 runs a structured engine that keeps every data point tagged, traceable
                and audit-ready.
            </p>

            <h3>2.1 Metabolic Timeline Engine</h3>
            <ul>
                <li>Unified timeline for glucose readings (fingerstick, CGM summaries), weight and waist measurements.</li>
                <li>Meal and snack events (time, type, estimated carb load, context tags like “eating out” or “late night”).</li>
                <li>Activity events (walks, cardio, strength, daily movement score) and sleep quality markers.</li>
            </ul>

            <h3>2.2 Medication &amp; GLP-1 Layer</h3>
            <ul>
                <li>Structured logging of GLP-1, insulin, metformin and other diabetes/metabolic medications.</li>
                <li>Dose, timing, frequency and side-effect notes captured in a consistent schema.</li>
                <li>Safe correlations: “this pattern often appears after dose day”, never “you must change dose”.</li>
            </ul>

            <h3>2.3 Risk &amp; Pattern Tags</h3>
            <ul>
                <li>Non-diagnostic pattern tags like “frequent highs after dinner”, “weight trending down slowly”, “low activity weeks”.</li>
                <li>Each tag linked to transparent rules that can be reviewed by clinicians and ministries.</li>
                <li>Support for comorbid patterns: blood pressure, sleep Apnoea risk, metabolic syndrome risk profile.</li>
            </ul>

            <p class="subtle">
                All data structures are designed from the start for evidence packs, WORM audit and safe integration
                with national diabetes programmes.
            </p>
        </section>

        <!-- 3. PEOPLE & CLINICAL JOURNEYS -->
        <section class="info-card">
            <h2>3. People &amp; Clinical Journeys Supported</h2>
            <p>
                Phase 9 is organised by real journeys, not only diagnoses.
            </p>

            <h3>3.1 Everyday Type 2 Diabetes Life</h3>
            <ul>
                <li>Daily overview of glucose ranges, meals and movement presented in simple colour-coded cards.</li>
                <li>Gentle nudges: “many of your highs this week are after late dinners” instead of judgemental tone.</li>
                <li>Support for shift workers, irregular schedules and real-world stress patterns.</li>
            </ul>

            <h3>3.2 GLP-1 &amp; Weight-Loss Journeys</h3>
            <ul>
                <li>Tracking of weight, waist, appetite, side-effects and energy across weeks and months.</li>
                <li>Context cards linking movement, sleep and weight change without promising magic results.</li>
                <li>Safe reminders to speak with clinicians before stopping or changing any medication.</li>
            </ul>

            <h3>3.3 Prevention &amp; High-Risk Populations</h3>
            <ul>
                <li>For pre-diabetes and metabolic risk, focus on lifestyle signals: food, movement, sleep, stress.</li>
                <li>Non-stigmatising language around weight and body image; no crash-diet messaging.</li>
                <li>Tools that can be rolled out via ministries, schools, workplaces and community programmes.</li>
            </ul>
        </section>

        <!-- 4. SAFETY, ETHICS & NON-DIAGNOSTIC BOUNDARIES -->
        <section class="info-card">
            <h2>4. Safety, Ethics &amp; Non-Diagnostic Boundaries</h2>
            <p>
                Diabetes and weight are emotionally heavy topics. Phase 9 is designed to be <strong>honest, kind
                and clinically responsible</strong> about what it can and cannot do.
            </p>

            <h3>4.1 Non-Diagnostic by Design</h3>
            <ul>
                <li>No statements like “you have diabetes”, “this is remission” or “your treatment is wrong”.</li>
                <li>Instead: “your pattern looks like…, here are questions to discuss with your healthcare team”.</li>
                <li>No insulin dose changes, no medication titration and no standalone treatment plans.</li>
            </ul>

            <h3>4.2 Emergency &amp; Red-Flag Behaviour</h3>
            <ul>
                <li>Critical signs (e.g. symptoms of severe hypo/hyperglycaemia, chest pain, breathing difficulty)
                    trigger clear “emergency help” messages.</li>
                <li>For mental health red flags (burnout, hopelessness, self-harm thoughts), Phase 9 pushes towards
                    crisis services and trusted support, never self-management tips.</li>
                <li>No dieting pressure, no shame language and no competitive leaderboards.</li>
            </ul>

            <h3>4.3 Privacy, Weight &amp; Stigma</h3>
            <ul>
                <li>Weight and glucose data are treated as highly sensitive; sharing is always explicit and reversible.</li>
                <li>Copy avoids moral judgements about food, body size or “willpower”.</li>
                <li>Focus is on sustainable habits, long-term health and small wins, not perfection.</li>
            </ul>
        </section>

        <!-- 5. DATA SOURCES & INTEGRATION -->
        <section class="info-card">
            <h2>5. Data Sources &amp; Integration With Other Phases</h2>
            <p>
                Phase 9 connects the metabolic picture with the rest of Elisence.
            </p>

            <h3>5.1 Inputs &amp; Devices</h3>
            <ul>
                <li>Manual logging for glucose, meals, activity and weight for low-resource settings.</li>
                <li>Integration-ready schema for CGM summaries, smart scales and wearables.</li>
                <li>Support for offline use with later sync when connectivity returns.</li>
            </ul>

            <h3>5.2 With Phase 3 (Care &amp; Weight-Loss)</h3>
            <ul>
                <li>Shared GLP-1 and weight-loss structures; Phase 3 focuses on lifestyle coaching,
                    Phase 9 on metabolic risk and patterning.</li>
                <li>Unified journey for citizens taking GLP-1 for both diabetes and obesity.</li>
            </ul>

            <h3>5.3 With Phase 6 (Global Medication Intelligence)</h3>
            <ul>
                <li>Medication knowledge from Phase 6 informs safety messages around combinations, timing and adherence.</li>
                <li>Clear separation: Phase 6 knows the drugs; Phase 9 organises the real-world behaviour around them.</li>
            </ul>

            <h3>5.4 With Phase 8 (AHE) &amp; Ministries</h3>
            <ul>
                <li>Anonymised, k-anonymous feeds into AHE for population-level metabolic insights.</li>
                <li>Enables dashboards such as “regions with highest out-of-range patterns” without exposing identities.</li>
                <li>Supports national programmes for prevention, GLP-1 funding and hospital readmission reduction.</li>
            </ul>
        </section>

        <!-- 6. INVESTOR & MINISTRY VALUE -->
        <section class="info-card">
            <h2>6. Why Phase 9 Matters for Investors &amp; Ministries</h2>
            <p>
                Diabetes and metabolic disease are among the biggest, most expensive health challenges in the world.
                Phase 9 is designed as a strategic engine for tackling that challenge safely.
            </p>

            <h3>6.1 Scale of the Problem</h3>
            <ul>
                <li>Hundreds of millions living with diabetes, many more at metabolic risk.</li>
                <li>Massive costs from complications, hospitalisations and loss of productivity.</li>
                <li>Fragmented tools, low adherence and poor visibility for ministries.</li>
            </ul>

            <h3>6.2 Differentiation vs Generic Diabetes Apps</h3>
            <ul>
                <li>Most consumer apps focus on graphs and ads; Elisence focuses on governance and real outcomes.</li>
                <li>Built to be ministry-grade: evidence packs, audit logs, zero-trust security and multi-language support.</li>
                <li>Designed to plug into public programmes, not compete with them.</li>
            </ul>

            <h3>6.3 Policy &amp; Programme Support</h3>
            <ul>
                <li>Supports value-based care models, GLP-1 reimbursement strategies and prevention campaigns.</li>
                <li>Provides anonymised data that can guide funding, education and infrastructure planning.</li>
                <li>Helps ministries show measurable impact to governments, donors and the public.</li>
            </ul>
        </section>

        <!-- 7. LIMITATIONS & SCOPE BOUNDARIES -->
        <section class="info-card">
            <h2>7. Limitations &amp; Scope Boundaries</h2>
            <p>
                To stay safe and globally deployable, Phase 9 deliberately keeps clear boundaries:
            </p>
            <ul>
                <li>Does not diagnose diabetes, remission or complications.</li>
                <li>Does not adjust insulin, GLP-1 or any other medication doses.</li>
                <li>Does not replace endocrinologists, diabetes nurses, dietitians or GPs.</li>
                <li>Does not act as emergency triage or crisis counselling by itself.</li>
                <li>Does not sell or share identifiable data with advertisers or data brokers.</li>
            </ul>
            <p>
                These limits protect citizens, protect clinicians and make it easier for ministries to adopt Elisence
                as a trusted, compliant platform.
            </p>
        </section>

        <!-- 8. ONE-SENTENCE SUMMARY -->
        <section class="info-card">
            <h2>8. One-Sentence Summary</h2>
            <p>
                Phase 9 is the <strong>Diabetes &amp; Metabolic Health Intelligence</strong> layer of Elisence – a
                multilingual, non-diagnostic engine that organises glucose, weight, medication and lifestyle data
                into safe, audit-ready patterns for citizens, clinicians and ministries around the world.
            </p>
        </section>

    </main>
</div>

<!-- Elisa chat widget root (Elisa appears in the bottom corner via elisa-chat.js) -->
<div id="elisa-chat-root"></div>

</body>
</html>
